Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology
We’ve raised our fair value estimates of Moderna and Merck stock.
Karen Andersen, CFA
Karen Andersen, CFA, is a director for Morningstar.
More From Karen Andersen, CFA
Novo Nordisk: What We Think of the Stock After Earnings
We are lowering our fair value estimate after reducing our long-term gross margin forecast, cagrisema expectations, and stage 2 growth assumptions.
Novo Nordisk: Trial Failure Disappointing, but Insignificant Portion of Our Forecast
We think shares look roughly fairly valued following their decline on July 31.
Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk
We’re lowering our fair value estimate of Novo stock.
Ahead of Earnings, Is Novo Nordisk Stock a Buy, a Sell, or Fairly Valued?
From obesity drug competition to pricing resets, here’s what we’re looking for in Novo Nordisk’s upcoming earnings report.
Why This Popular US Stock Is a Sell
When a great company’s stock is trading at a not-so-great price.
Roche Earnings: Raising Our Valuations as Broad Giredestrant Launch in 2027 Comes Into Focus
We think Roche stock is moderately undervalued.
Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy
We’ve lowered our fair value estimate of Novo stock.
Novo Nordisk Earnings: We’re Lowering Our Fair Value Estimate Despite Wegovy Pill Strong US Launch
We think Novo Nordisk stock is moderately undervalued.
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative
We’ve lowered our fair value estimate of Pfizer stock.
Roche Earnings: Continuing Steady Underlying Growth in 2026 as Late-Stage Pipeline Shines
We think Roche stock is moderately undervalued.
Ahead of Earnings, Is Novo Nordisk Stock a Buy, a Sell, or Fairly Valued?
Investors will focus on the US launch of the Wegovy pill, 2026 guidance, and Novo’s rivalry with Eli Lilly.
US Healthcare: Increased Clarity on Drug Pricing and Tariffs, Solid Performance Expected for 2026
In this US sector, our top picks include GE Healthcare and IQVIA.
Novo and Lilly: FDA Approval of Wegovy Pill Launches New Obesity Battle
This launch—and the recent cagrisema filing—should help Novo regain its footing against Lilly.
Novo Nordisk: Alzheimer’s Failure Puts More Pressure on Oral Semaglutide Launch in Obesity
We think Novo Nordisk stock is moderately undervalued.
Novo Nordisk and Eli Lilly: New Obesity Drug Prices, Orforglipron Voucher, and Eloralintide Data
We update our Fair Value Estimates for the two pharmaceutical giants.
Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies
We continue to embed the Metsera pipeline in our model for Pfizer.
Novo Nordisk: Confirmed as Other Leading Metsera Bidder, Now Publicly Fighting for Deal
We think Novo Nordisk stock is moderately undervalued.
Roche Earnings: We’re Slightly Lowering Our 2025 Sales Forecast but Encouraged by Diverse Pipeline
We think Roche stock is significantly undervalued.
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition
We think Novo Nordisk stock is moderately undervalued.
Pfizer: First Out of the Gate With a Drug Pricing Agreement; Positioned to Avoid Major Headwind
Shares remain undervalued.
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds
We lower our fair value estimate for both companies.
Eli Lilly: Strong Orforglipron Data in Second Obesity Trial Support On-Schedule Regulatory Filings
Lilly shares rose nearly 5% and Novo shares fell a similar amount in intraday trading.
Eli Lilly Earnings: Weak Orforglipron Obesity Data Weighs Down a Strong Quarter
With today’s share drop, we think Lilly stock looks fairly valued.
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty
We think Novo Nordisk stock is undervalued.
Pfizer Earnings: Impressive Q2 Results Bolster 2025, but Awaiting More Pipeline Data
Pfizer stock remains undervalued.
Biopharma and US Policy: Tariffs Increasingly Manageable; Medicaid Pricing Policy Looks Unrealistic
No changes to fair value estimates and wide-moat take on Roche, Novo Nordisk, and Eli Lilly.
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition From Compounded Semaglutide
We’ve lowered our fair value estimate of Novo stock.
Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation
We’re cutting our fair value estimate to DKK 552 after lowering our near-term Wegovy sales estimates.
Novo Nordisk: CEO’s Surprise Departure Points to Challenging Obesity Market Dynamics
Leadership shake-up signals uncertainty amidst intensifying competition in obesity market.
